Clinical Trial Update: A Trial of Anti-TNF Chimeric Monoclonal Antibody (cA2) in Korean Patients With Active Rheumatoid Arthritis Despite Methorexate (Extension Part)(Study P05645)(COMPLETED) [Phase 3]

View source ↗

Summary

Phase 3 extension study of the anti-TNF chimeric monoclonal antibody cA2 in Korean patients with active rheumatoid arthritis despite methotrexate has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• cA2

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Arthritis, Rheumatoid | Phase 3 | Status: COMPLETED | Results posted: 2009-07-21